• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Euro Surveill. Prevalence of IgM and IgG antibodies to West Nile virus among blood donors in an affected area of north-eastern Italy, summer 2009

Giuseppe

Emeritus
Prevalence of IgM and IgG antibodies to West Nile virus among blood donors in an affected area of north-eastern Italy, summer 2009 (Euro Surveill., abstract, edited)


[Source: Eurosurveillance, full text: <cite cite="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19814">Eurosurveillance - View Article</cite>. Abstract, edited.]

Eurosurveillance, Volume 16, Issue 10, 10 March 2011

Surveillance and outbreak reports

Prevalence of IgM and IgG antibodies to West Nile virus among blood donors in an affected area of north-eastern Italy, summer 2009

P Pezzotti 1, C Piovesan 2, L Barzon 3,4, R Cusinato 4, M Cattai 4, M Pacenti 4, A Piazza 4, E Franchin 3,4, S Pagni 3,4, S Bressan 4, T Martello 4, R Potenza 5, C Scipioni 5, R Ammendola 5, A Breda 6, G Pal? 3,4, F Russo 2, G Rezza 7

1. Lazio Sanit? ? Agenzia di Sanit? Pubblica (Public Health Agency), Rome, Italy
2. Direction of Prevention, Veneto region, Venice, Italy
3. Department of Histology, Microbiology, and Medical Biotechnologies, University of Padua, Padua, Italy
4. Regional Reference Centre for Infectious Diseases, Microbiology and Virology Unit, Hospital of Padua, Padua, Italy
5. Dipartimento Interaziendale di Medicina Trasfusionale (DIMT; Interinstitutional Department of Transfusion Medicine), Local Health Unit AUSL 18-19, Rovigo, Italy
6. Coordinamento Regionale per le Attivit? Trasfusionali (CRAT; Regional office for the coordination of blood transfusions), Pieve di Soligo, Italy
7. Department of Infectious Diseases, Istituto Superiore di Sanit?, Rome, Italy

Citation style for this article: Pezzotti P, Piovesan C, Barzon L, Cusinato R, Cattai M, Pacenti M, Piazza A, Franchin E, Pagni S, Bressan S, Martello T, Potenza R, Scipioni C, Ammendola R, Breda A, Pal? G, Russo F, Rezza G. Prevalence of IgM and IgG antibodies to West Nile virus among blood donors in an affected area of north-eastern Italy, summer 2009 . Euro Surveill. 2011;16(10):pii=19814. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19814

Date of submission: 10 January 2011


Following reports of West Nile neuroinvasive disease in the north-eastern area of Italy in 2009, all blood donations dating from the period between 1 August and 31 October 2009 in the Rovigo province of the Veneto region were routinely checked to exclude those with a positive nucleic acid test for West Nile virus (WNV). Only one of 5,726 blood donations was positive (17.5 per 100,000 donations; 95% confidence interval (CI): 0.4?97.3). In addition, a selection of 2,507 blood donations collected during the period from 20 July to 15 November 2009 were screened by ELISA for IgG and IgM antibodies against WNV. A positive result was received for 94 of them. The positive sera were further evaluated using immunofluorescence and plaque reduction neutralisation test (PRNT), in which only 17 sera were confirmed positive. This corresponds to a prevalence of 6.8 per 1,000 sera (95% CI: 4.0?10.9). In a case-control study that matched each of the 17 PRNT-positive sera with four negative sera with the same date of donation and same donation centre, we did not find a significant association with age and sex of the donor; donors who worked mainly outdoors were significantly more at risk to have a positive PRNT for WNV.

-
-------
 
Back
Top